by Raynovich Rod | Aug 5, 2024 | 2025 Rayno Biopharmaceuticals Portfolio
8/12/24…COMING SOON MARKET DATA ON BIOTECH STOCKS UPDATE on Large Caps since ASCO. Did you buy or add to ABBV, GILD,LLY? Which SMID biotechs still have Momentum? ADPT,CPRX,NTRA etc. ===== Update-2 8/9/24 10:45 a EDT: EVH soars on revenue beat with an increase...
by Raynovich Rod | Jul 8, 2024 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-3 …7/11…SMID biotechs rally on a big rotation day out of MEGA Cap tech.XBI up 2.67% “kissing” the $98 level.Nibble on our Life Science trading list as it is another “green screen ” day. Even the IBB broke through $140 today...
by Raynovich Rod | Jun 10, 2024 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Healthcare stocks
Update-4…6/29….I’m back but I did not miss much in biotech trades, but a lot of “3 day wonders'” you know stocks that get momentum then quickly fade. The XBI is still holding above the $90 support level with a range of $89.13 to $94.88...
by Raynovich Rod | May 20, 2024 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
UPDATE 3: Large cap biopharmas were strong on Friday in anticipation of #ASCO24 data. Company news to watch from data below:AZN, BMY, GILD, LLY, MRK, PFE,REGN and also ADPT, MRUS, NVS. REPL.. See updates all next week. Update-2 MAY 31,,,Biopharma stocks took a dip...
by Raynovich Rod | Jan 15, 2024 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-3 1/19/24 2:45 EST ……XBI trying to bottom at $87 handle, but consider test providers in light of pick up in patient utilization of healthcare DHR ,TMO. NAZ up 1.5% on huge tech rally. AMD at all time high at $170. Update-2 1/18/24,,,11:15 EST…...
by Raynovich Rod | Oct 16, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 10/20 Merck (MRK) pops over 2% to $102+ on ADC deal with Daiichi Sankyo. Collaboration combines Daiichi Sankyo’s proven ADC expertise and DXd technology with Merck’s deep experience in oncology and clinical development capabilities to advance and expand the...
by Raynovich Rod | Oct 9, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-4 10/17…JNJ now reporting as a stand-alone biopharmaceutical and medical device Company raised its profit forecast helped by demand from it anti-inflammatory drug Stelara and reported a gain of $21 B from the spin-off of its consumer health unit Kenvue....
by Raynovich Rod | Aug 29, 2023 | 2024-25 Life Science Portfolios
Update-1 9/2 Biotechs nudge off bottom with IBB at 3 month high at $130 level. FTC concedes Amgen fight over Horizon deal. XBI finds an uptick of 2.44% to $81 handle on Friday. MedTech still sluggish with IHI in low fifties in choppy trading all year. Novartis joins...
by Raynovich Rod | Jul 24, 2023 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios
Hot fun in the summertime! Will try to post a new article on Healthcare and Biotech tomorrow August 7. Update-4 Aug 3…Large cap biopharmas favored as spec stocks fade with XBI at $81 handle lacking momentum, near low for 30 days. Earnings looking good for...
by Raynovich Rod | Jul 17, 2023 | 2024-25 Life Science Portfolios
Update-2 Jy 22 Catch-up Rally last week continues in MedTech and Diagnostics: ABT our top pick up 5.89% to $114.29, DHR up 6.38% to $255.88,IHI up 1.32% to $57.59,TMO up 6.89% to $562. New Pick Becton Dickinson (BDX) up 2.1% to $264.84. Earnings coming next week...
